同位素 ›› 2020, Vol. 33 ›› Issue (6): 366-373.DOI: 10.7538/tws.2019.youxian.071

• 同位素制备与分离专栏 • 上一篇    下一篇

125I生产工艺研究进展与展望

李波;罗宁;曾俊杰;吴建荣;贾致军;王磊;孙志中;陈云明;张劲松   

  1. 中国核动力研究设计院,成都610213;四川省放射性同位素工程技术研究中心,成都610213
  • 出版日期:2020-12-20 发布日期:2021-01-04

125I Production Technology: Current Status and Future Perspective

LI Bo;LUO Ning;ZENG Junjie;WU Jianrong;JIA Zhijun;WANG Lei;SUN Zhizhong;CHEN Yunming;ZHANG Jingsong   

  1. Nuclear Power Institute of China, Chengdu 610213, China;Radioisotope Engineering Technology Research Center of Sichuan, Chengdu 610213, China
  • Online:2020-12-20 Published:2021-01-04

摘要:

125I是一种重要的医用放射性核素,由于其半衰期较长(T1/2=59.4 d),γ射线能量低、无β辐射,对人体组织产生的辐射损伤小等优点,使其在生物医学、放射免疫体外诊断和近距离植入治疗肿瘤等方面得到了广泛应用。本文简要介绍125I的生产原理、国内外生产工艺研究现状、国内市场需求,并展望125I的生产前景。

关键词: 125I, 反应堆, 放射性核素, 近距离植入治疗, 肿瘤

Abstract:

Iodine-125(125I) is one of the most attractive and significant radionuclide that is widely used in biomedical, radioimmunoassay in vitro diagnosis and brachytherapy for tumors owing to its favorable nuclear characteristics, including low energy X-ray, no β-ray, less radiation damage. In this paper, the process and current status of 125I production technology, demand of domestic market and the prospect of 125I were briefly introduced.

Key words: idoine-125, nuclearreactor, radioisotope, brachytherapy, cancer